Laboratory Medicine Updates - December 6, 2004
University of Virginia Health System
“Quality You Expect, Service You Deserve”
LABORATORY MEDICINE UPDATE
December 6, 2004
Change in Glucose Tolerance Procedure Cut-offs
Current ADA and NACB guidelines place the upper limit of the reference interval for a fasting glucose at 100 mg/dL. In pregnancy, a fasting glucose value greater than 110 mg/dL is diagnostic for gestational diabetes. In the general population, a fasting glucose value greater than 126 mg/dL is diagnostic for diabetes.
Based on these guidelines, in the OB setting, a glucose tolerance test (test code OBGTT) will not be performed if the fasting glucose is >110 mg/dL. In the general population, a glucose tolerance test will not be performed if the fasting glucose is >126 mg/dL.
Physicians requesting this testing on their patients will be notified if the test must be cancelled.
Medicare will cover an annual screening PSA test for men over 50. The screening procedure requires that the diagnosis of V76.44 appear on the claim, effective October 1, 2004. The test request form should indicate specifically PSASC or PSA-screening.
Under a National Coverage Decision by Medicare, a diagnostic PSA (test code PSA) may be used (1) to monitor patients with prostate cancer, (2) in the differential diagnosis of men presenting with as yet undiagnosed disseminated metastatic disease, or (3) in conjunction with other tests such as digital rectal examination, in the diagnosis of prostate cancer. When a diagnostic PSA test is requested, it should be submitted with the appropriate diagnosis code for the patient’s condition, for example diagnosis code 185 or 602.9.
Laboratory Relocation Update
Construction of the new building that will house the relocated Core, Microbiology and Molecular Diagnostics Laboratories continues, and completion is still scheduled for mid-February 2005.
The physical relocation of all the laboratory equipment is being coordinated to ensure that there is no disruption to essential laboratory services during the move. To facilitate a smooth transition to the new location, a new “Express” pneumatic tube system connecting the new lab building to the main hospital will be installed prior to the move. The tube station that is currently housed in Central Receiving in the main hospital will continue to operate until after the relocation has successfully taken place.
For additional information or questions regarding the upcoming relocation please contact Cavell Kopetzky in Medical Laboratories Administration at 434-243-2649 (email: email@example.com).